Agios Pharmaceuticals, Inc. (AGIO) vs Vericel Corporation (VCEL)

Agios Pharmaceuticals, Inc. and Vericel Corporation are both Biotechnology companies. Agios Pharmaceuticals, Inc. and Vericel Corporation are of similar size ($2.0B and $2.0B). Agios Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Vericel Corporation trades at 82.6×. Agios Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 140.6% against 23.0%. Vericel Corporation has the higher net margin (7.91% vs −418.2%) and the higher return on invested capital (5.49% vs −70.2%). Across the 18 metrics below, Vericel Corporation leads on 14 and Agios Pharmaceuticals, Inc. on 4.

Valuation

Metric AGIO VCEL Biotechnology median
P/E n/m 82.63 7.88
P/S 19.71 6.61 11.47
P/B 1.89 5.47 2.52
Price to free cash flow n/m 32.85 21.16
EV/EBITDA n/m 62.29 0.74
EV/Sales 14.05 6.36 10.73
Earnings yield (21.52%) 1.21% (28.84%)
Free cash flow yield (18.85%) 3.04% (23.03%)

Profitability

Metric AGIO VCEL Biotechnology median
Gross margin 91.99% 74.56% 65.16%
Operating margin (466.78%) 5.95% 0.00%
Net margin (418.24%) 7.91% 0.00%
Free cash flow margin (371.43%) 20.13% 0.00%
Return on equity (34.34%) 7.16% (57.72%)
Return on assets (31.89%) 5.16% (49.22%)
Return on invested capital (70.24%) 5.49% 0.00%

Growth

Metric AGIO VCEL Biotechnology median
Revenue growth (TTM) 140.58% 22.95% 5.64%
EPS growth (last fiscal year) (161.17%) 60.00% —
Revenue growth, 5-year CAGR (14.45%) 17.34% 8.40%
Net income growth, 5-year CAGR 0.00% 41.97% 0.00%

Health

Metric AGIO VCEL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 10.22 5.04 4.73
Net debt to EBITDA 1.80 (6.08) 0.96

Dividend

Metric AGIO VCEL Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric AGIO VCEL Biotechnology median
Market cap 2.00b 2.03b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack